AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04442503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 oral capsules.
Study NCT04442503 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matched-placebo oral capsules.
Study NCT03393754 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccination
Description: Prophylactic Hepatitis B Vaccination
Study NCT03393754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccination
Description: Prophylactic Hepatitis B Vaccination
Study NCT01576458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ursodeoxycholic acid
Description: 450 mg/day for 14 days
Study NCT01576458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01816230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiCord®
Study NCT01167335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492
Study NCT01167335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04083326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Patient Journey Solution
Description: Patients in the intervention arm are provided with a digital patient journey solution used on a mobile device. The application is intended to be used during the whole care path. The patient can familiarize him-/herself to the phases of care through visual timeline representation of the care path, get information on how to prepare for a surgery, receive reminders, fill in questionnaire forms, communicate with the care personnel via messaging functionality and video calls, and search information from frequently asked questions. The application contains information about the preparation, forms for anamnesis, anesthesia and treatment follow-up, information videos and pictures, and timely and individually-tailored reminders, e.g., on when to stop eating and drinking before the surgery. In addition, the application provides instructions on how to arrive to the treatment unit and comprehensive guidance for wound care and rehabilitation at home after the operation.
Study NCT02035163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two sites cryoablation
Description: Two ganglionic plexi around atrium was performed with 90-second cryoablation.
Study NCT01904513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pasteurized Whole Milk
Study NCT01904513 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR-1
Study NCT01567553 — intervention group
Intervention type: OTHER
Intervention: USPIO MRI - Gadolinium MRI
Description: USPIO MRI scanning will be performed at :~* baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.~* baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,~* baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,~* baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,~* baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.~Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36.
Study NCT03169816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Lorcaserin 10mg, twice daily
Study NCT03169816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo for lorcaserin condition dosed twice daily
Study NCT03828539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: 70mg/1mL (70 mg) or 2x70mg/1mL (140 mg) in pre-filled syringe, administered every 4 weeks
Study NCT03828539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Film-coated tablet taken orally:~25 mg administered once daily (first week of titration phase). After the first week, titration was done according to the summary of product characteristics (SmPC) in 25 mg increments each week and aimed to reach the recommended daily treatment dose of 100 mg (50/75/100 mg). 50/75/100 mg were administered twice daily during titration phase and maintenance phase.
Study NCT03828539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab matching placebo
Description: Erenumab matching placebo pre-filled syringue administered every 4 weeks
Study NCT03828539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate matching placebo
Description: Topiramate matching placebo administered daily
Study NCT01659073 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Stimulation
Study NCT01345539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Patients may have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met.
Study NCT01345539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy choice of agents is at the discretion of the treating medical oncologist.
Study NCT03750448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation
Description: The telerehabilitation intervention is based on sensor technology, developed by ICURA. The technology consists of motion sensors that can measure and analyse the quantity and quality of the exercises, and a mobile application that can guide the patients with visual response. A unique feature of ICURA trainer allows the physiotherapist to remotely supervise the individual patients exercise adherence and progress. The patients will receive a suitcase with five sensors (to be placed bilaterally on lower legs, thighs and one around the waist), a smartphone to record the exercises and a charging station free of charge during the 6-week intervention. At the end of the intervention the material will be returned at the first follow-up (t1). For more information please visit https://icura.dk.
Study NCT03750448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Patients allocated to the no intervention group will receive encouragement to stay active and be encouraged to gradually return to activities of daily living. This will be the only exercise-encouragement given to the no-intervention group.
Study NCT03750448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised rehabilitation
Description: The unsupervised rehabilitation group will receive a written exercise program in order to perform daily exercises at home. The exercise program will be made using Exorlive (for more information about Exorlive please visit https://www.exorlive.com). In addition to the written program, patients will able to use a link provided to see small video-instructions on the internet of each exercise on the program. No feedback or supplementary instructions will be given after the initial face-to-face appointment.
Study NCT02553863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture for 30min \[twice weekly for 8 weeks\]
Study NCT02553863 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard care
Description: Standard care
Study NCT04119154 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast Microhalography (CEM)
Description: Fine needle aspirates evaluated by CEM device
Study NCT01110655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous hypertonic Saline
Description: Intravenous 100mL bolus of 3% saline
Study NCT01110655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral hypertonic saline
Description: Oral 100mL bolus of 3% saline
Study NCT00439465 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ex-vivo expanded effector cells
Description: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
Study NCT03504930 — intervention group
Intervention type: OTHER
Intervention: Impact of biotherapy on postoperative morbidity in ulcerative colitis
Description: Impact of biotherapy on postoperative morbidity, quality of life, sexual function, sexual health in ulcerative colitis
Study NCT02037152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body scan exercise
Description: The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions.
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Given PO
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Given PO
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03737994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO
Study NCT03816163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolbetuximab
Description: Administered as an intravenous infusion.
Study NCT00176865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Description: 500 mg/kg IV weekly beginning on Day +7 until Day +100
Study NCT03816163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Administered as an intravenous infusion
Study NCT03816163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Administered as an intravenous infusion
Study NCT03816163 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: Administered as an intravenous infusion
Study NCT03816163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered as an intravenous infusion
Study NCT03366883 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin Plus 5-FU (TCF)
Description: preoperative chemotherapy with three cycles of TCF(Paclitaxel 135mg/m2 D1;Cisplatin 60mg/m2 D1 or 20mg/m2 D1-D3;5-fluorouracil 600mg/m2 D1-D5；repeated every 3 weeks)
Study NCT03366883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiochemotherapy
Description: preoperative radiochemotherapy (41.4 Gy/23 fractions or 40 Gy/20 fractions) with four cycles of TP(Paclitaxel 45mg/m2 on D1 and Cisplatin 20mg/m2 D1,repeated every week)
Study NCT00534911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.~Other Name: Primary and secondary coping enhancement training (PASCET)
Study NCT00534911 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Non-directive Therapy (SNDT)
Description: SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
Study NCT03187561 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Infant sleep-adapted coparenting intervention
Description: The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
Study NCT03187561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant sleep-adapted coparenting intervention
Description: The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
Study NCT02426385 — intervention group
Intervention type: DEVICE
Intervention: FineVision Toric
Description: Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
Study NCT01092455 — intervention group
Intervention type: DRUG
Intervention: Heparin N reduction
Description: Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
Study NCT03867760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded Hypnosis Intervention
Description: The RHI consists of four digital recordings developed by the investigator using standardized hypnosis scripts for pain reduction and uploaded to a MP3 player. The scripts were developed for patients with chronic pain and tested by a psychologist who is an expert in hypnosis research. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days). The script includes an induction, suggestions for how to access inner resources and manage pain, and post-hypnotic suggestions for permanence of hypnosis benefits and self-hypnosis practice.
Study NCT03867760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recorded Relaxation Intervention
Description: The recorded relaxation intervention consists of four digital recordings developed by the investigator using standardized relaxation scripts and uploaded to a MP3 player. Participants will listen to the recordings daily for 28 days in the prescribed order (4 recordings for 3 days each, and then any recording for the remaining 16 days).
Study NCT01717352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Education
Study NCT01717352 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Eating Routine
Study NCT02589067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
Study NCT02589067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
Study NCT01426854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac Ophthalmic Suspension, 0.1%
Description: Topical ocular administration
Study NCT01426854 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nepafenac Vehicle Ophthalmic Solution
Description: Inactive ingredients used as placebo; topical ocular administration
Study NCT01261949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined frontal and temporal rTMS
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
Study NCT01261949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Temporal low frequency rTMS
Description: Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
Study NCT02955901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 day low residue diet prior to the colonoscopy
Description: 3 day low residue diet prior to the colonoscopy
Study NCT02955901 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 1 day low residue diet prior to the colonoscopy
Description: 3 day low residue diet prior to the colonoscopy
Study NCT00493805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization
Study NCT00493805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of pegylated interferon alfa-2b and ribavirin
Description: 1. Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks~2. 200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks
Study NCT00604162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam COLON
Description: The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
Study NCT00604162 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard colonoscopy
Description: Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
Study NCT04032418 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT04032418 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03303781 — intervention group
Intervention type: OTHER
Intervention: Cardiac Rehabilitation
Description: phase II center-based cardiac rehabilitation
Study NCT03721718 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLS-5300
Description: \[Part A\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) \[Part B\] GLS-5300 0.3 mg at 0, 4, and 12 weeks (N=5) GLS-5300 0.6 mg at 0, 4, and 12 weeks (N=25) GLS-5300 0.6 mg at 0 and 8 weeks (N=25)
Study NCT03721718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellectra 2000 Electroporation
Description: GLS-5300 administered ID followed by Cellectra 2000 Electroporation
Study NCT05406050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reference eldecalcitol soft capsule
Description: 0.75 μg, produced by Chugai Pharmaceutical Co., Ltd. Japan
Study NCT05406050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: test eldecalcitol soft capsule
Description: 0.75 μg, produced by Wenzhou Haihe Pharmaceutical Co., Ltd. China
Study NCT02273492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asasantin ER
Study NCT02273492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asasantin ER
Study NCT02273492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized breakfast
Study NCT01007994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: New Medication: Enalapril, Isradipine, Propranolol
Description: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.~Dosing will be as follows:~ACEI: Enalapril \< 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine \< 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol \<40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg
Study NCT03193021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiva Mid-Bore VVCS
Description: The device will be used to close all femoral venous access sites at the end of the case, which range from 3 - 4 access sites per patient.
Study NCT03193021 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual compression
Description: Manual compression will be used to achieve hemostasis in all femoral venous access sites when the sheaths are pulled, which range from 3-4 access sites per patient.
Study NCT04483921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute exercise
Description: Participants will complete a morning exercise bout at 70% of their individual maximal aerobic capacity to burn 200 kilocalories above their basal metabolic rate.